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Optimization of a multiple Water-in-Oil-in-Water Nanoemulsion 
Encasing Bacteriophages for Inhalational Antibiotherapy
Abstract
Experimental procedures
PREPARATION OF MULTIPLE BACTERIOPHAGE T4-ENCASING LIPID NANOEMULSIONS.
Production of multiple emulsions encompassing lipid nanovesicles with encased T4-
bacteriophages was carried out using an Ultra Turrax (model T25D from IKA) under 
heating (ca 40ºC) (see Figure 1). T4-bacteriophages were suspended in the (inner) 
aqueous phase (Win) and then dispersed in the melted oil phase, via high-speed 
homogenization (10 min at 9000 rpm). The resulting W/O emulsion was further 
dispersed in the outer aqueous phase, via another homogenization cycle. The inner 
aqueous phase encompassed HCl 10 mM (from Vaz Pereira), Tween 80 (from Sigma-
Aldrich) and impure lyophilized T4-bacteriophages (5 mg); the intermediate oily phase 
encompassed glycerol (from Merck, Darmstadt, Germany), Softisan™ 100 (from 
Sasol Olefins & Surfactants GmbH, Hamburg, Germany) and soybean 
phosphatidylcholine (from Acofarma, Spain); finally, the outer aqueous phase 
encompassed Lutrol™ F68 (poloxamer 188 from BASF, Germany) and ultrapure 
water. 
Experimental results and discussion
Replacement of the poloxamer by Lutrol F-127 led to a substantial decrease (from 
more negative towards less negative values) in the negativity of the Zeta Potential of 
the lipid nanovesicles.
Increasing Tween 80 concentration, up to 40% of the departing concentration, led to 
more negative Zeta Potential values, but the lipid nanovesicles seemed to be 
unstable over storage time, with notorious disaggregation (see Figure 3).
The effect of simultaneously increasing the amounts of Tween 80 and lecithin were 
implicit in the high increase of Zeta Potential (from more negative towards less 
negative values), presumably due to accumulation of adsorbed ions at the particle 
surfaces. A lower concentration of Tween 80 proved to be suitable in producing lipid 
nanovesicles with stabler Zeta Potential and higher hydrodynamic sizes, throughout 
storage time.
In this research effort, development and optimization of lipid nanovesicles encasing 
bacteriophage-T4 was pursued. A lipid with a mild melting temperature, 
encompassing medium-to-long chain fatty acid moieties was found most 
appropriate for the discontinuous oily phase. A homogenization timeframe of 10 
min, the use of a low concentration of Tween 80, and low bacteriophage 
concentrations were found to be critical processing variables for producing stable 
nanovesicle dispersions with diameters ranging from 115-145 nm and Zeta Potential 
values of ca. -16 mV. Inclusion of these multiple nanoemulsions in isotonic 
formulations for inhalational therapy of pharyngo-tonsillitis would possess inherent 
advantages, when compared with the current chemical antimicrobial approach, if 
bacteriophage-T4 were to be replaced by a lytic phage specific for Streptococcus 
pyogenes, in that bacteriophages are naturally harmless entities with bacteriostatic 
activity, without any toxicological risk for humans.
Conclusions
Infectious bacterial diseases still remain the main cause of human premature deaths, 
especially in developing countries. The emergence and spread of pathogenic bacteria 
resistant to many chemical antibiotics (multidrug- resistant strains) have created the 
need for the development of novel therapeutic agents. Bacteriophages have proven to 
be an interesting and effective alternative in the management of persistent bacterial 
infections where conventional chemical antibiotherapies fail. The lethality and 
specificity of bacteriophages for specific bacteria, their ability to replicate within 
bacterial hosts and safety of these human-friendly viruses makes them highly lethal 
antibacterial agents, besides being efficient and relatively cost-effective.
Group A streptococci (GAS) are serious human pathogens that cause infections 
ranging from mild pharyngitis, tonsillitis, to chronic rheumatic heart disease and, in 
some cases, severe streptococcal toxic shock syndrome and necrotizing fasciitis. The 
frequency and severity of GAS infections has been increasing over the last decades, 
which has promoted extensive research on the improvement of naturally occurring 
antimicrobials as alternatives to their conventional chemical counterparts.
In this research effort, development and optimization of a biotechnological process for 
the inhalational administration of a bacteriophage was pursued, using strategies of 
nanoencapsulation within lipid nanovesicles. This method of targeting may have a high 
potential for the treatment of bacterial infections of the respiratory tract, caused mainly 
by Streptococcus pyogenes. As a proof-of-concept for the nanoencapsulation strategy, 
and since there is not yet available a strictly lytic bacteriophage cocktail for 
Streptococcus pyogenes, a well-defined and characterized bacteriophage was utilized, 
viz. bacteriophage T4.
Water-in-oil-in-water (W/O/W) multiple emulsions are nanosystems in which 
dispersions of small water droplets within larger oil droplets are themselves dispersed 
in a continuous aqueous phase. Due to their compartimentalized internal structure, 
multiple emulsions present important advantages over simple O/W emulsions for 
encapsulation of biomolecules, such as the ability to carry both polar and non-polar 
molecules, and a better control over releasing of therapeutic molecules. Bacteriophage 
T4 was accordingly entrapped within W/O/W multiple nanoemulsions, aiming at 
mimicking the multifunctional design of biology, optimized with several lipid matrices, 
poloxamers and stabilizing layer compositions. Physicochemical characterization of the 
optimized bacteriophage-encasing nanovesicle formulations encompassed 
determination of particle (hydrodynamic) size, size distribution and particle charge 
(Zeta potential), via Dynamic Light Scattering analysis, surface morphology via Cryo-
SEM, and thermal analysis via DSC, whereas antimicrobial activity of the 
nanoemulsions produced were evaluated via the “spot-test” using appropriate bacterial 
cultures.
OPTIMIZATION OF THE NANOFORMULATION
Several variables were studied, viz. lipid nature, poloxamer nature, soy lecithin 
concentration and  tween 80 concentration.
OPTIMIZATION OF THE FORMULATION PARAMETERS.
Optimization of the multiple lipid nanoemulsion proceeded via preparation of different 
emulsions with different Tween 80 concentrations (50 to 75 mg) and different 
stabilizing layer compositions (see Table 1).
DETERMINATION OF HYDRODYNAMIC SIZE (HS) AND ZETA POTENTIAL (ZP).
Determination of the HS of the lipid nanovesicles produced, of the polydispersion 
index and of their ZP were carried out in a Zetasizer (model Nanoseries Nano-ZS) 
from Malvern Instruments.
THERMAL ANALYSIS BY DIFFERENTIAL SCANNING CALORIMETRY (DSC).
Calorimetric analyses of the nanoemulsions produced were performed in a differential 
scanning calorimeter (Shimadzu, Kyoto, Japan), which comprised a detector 
(DSC-50) and a thermal analyzer (TA-501). The samples were heated from room 
temperature to 100 ºC at a constant linear rate of 5 ºC/min, during which the amount 
of heat absorbed by the samples was recorded.
EVALUATION OF ANTIMICROBIAL ACTIVITY BY THE “SPOT” METHOD.
Optimized nanoemulsions were assessed for antimicrobial (lytic) activity, following a 
simple laboratory procedure. Whole nanoemulsions were submitted to the “spot” test 
as follows; 1. 100 !L of bacterial suspension (Escherichia coli) grown overnight at 37 
°C were added to 3 mL of top-agar; 2. Following a gentle homogenization, the top 
agar added with bacterial suspension was poured into a 90 mm Petri dish previously 
prepared with 10 mL bottom-agar and allowed to dry; 3. A 5-!L drop of the whole lipid 
nanoemulsion was then applied and allowed to dry; 4. Incubation of the Petri dish was 
then allowed at 37 °C, overnight.
Figure 1. Experimental 
setup utilized for the 
preparat ion of l ip id 
nanovesicles encasing 
T4-bacteriophages.
Figure 2. Physical appearance of the 
lipid nanovesicles (Water-in-Oil-in-
Water multiple nanoemulsion), as 
observed under an optical microscope 
at maximum resolution (x100).
Figure 9. Changes in Intensity throughout Particle Hydrodynamic Size.
Table 1. Optimization of processing conditions leading to an optimal 
nanoformulation encasing T4-bacteriophage.
HYDRODYNAMIC SIZE AND ZETA POTENTIAL DETERMINATIONS
Both the Hydrodynamic size and Zeta Potential of the several nanoemulsions 
produced were evaluated and followed throughout a prolonged storage at room 
temperature. The results obtained are displayed in Figures 3 and 4.
Figure 3. Changes in particle hydrodynamic size throughout storage time.
Figure 4. Changes in Zeta Potential values throughout storage time.
ANTIMICROBIAL ACTIVITY DETERMINATIONS
The preliminary results obtained for the antimicrobial (lytic) properties of the optimized 
nanoemulsion encasing bacteriophage-T4 are displayed in Figure 5 (see inserted 
arrow), clearly showing the inhibition halo produced by the whole nanoemulsion.
Figure 5. Petri dish after performance of the “spot” test to the nanoemulsion encasing 
bacteriophage T4.
ELECTRON SCANNING MICROSCOPY ANALYSES
Lipid nanoemulsions were analyzed for microstructural and morphological 
characteristics via Cryo-SEM. Briefly, nanoemulsion samples were prepared for 
analysis as follows: (i) samples were mounted in an appropriate (aluminum) support 
inserted into a gold-coated plate; (ii) the gold-coated plate was then duly fixed in a 
transfer stick; (iii) the support containing the sample was immersed in liquid nitrogen 
(slush nitrogen); (iv) the sample was then transferred under vacuum into the SEM 
preparation chamber (also under vacuum and maintained cold via addition of liquid 
nitrogen); (v) inside the chamber, the deep-frozen sample was fractured, undergone 
sublimation (during 90 s to 300 s) by gently increasing the temperature from -140 °C 
to ca. -90 °C, and was coated with Au/Pd; (vi) finally, the sample was transferred into 
the SEM chamber for microscopy analysis. 
Since we aimed at entrapping a bioactive lytic phage within the lipid nanovesicles, a 
lipid was chosen so as to melt down at a lower temperature, viz. Softisan 100™. 
Figure 6. Preparation of nanoemulsion samples for cryo-SEM analysis.
Figure 7. Cryo-electron scanning microphotographs of bacteriophage T4-encasing 
nanoemulsions.
MICROCALORIMETRIC ANALYSIS OF THE NANOFORMULATIONS
We have made two T4-bacteriophages suspensions oone with and one without 
homgenization and we evaluated the  changes in Intensity throughout Particle 
Hydrodynamic Size(see Figure 3 and 4). It was found in both case the existence of 
particles with smaller size (28,2-78,8nm) and greater (255-396nm) than  the T4-phage 
size (200nm).The weighted average was 164.5 and 219.3, respectively, of phage 
suspension with and without homogenization. The smaller size, is derived from the 
decay of phages and cellular debris from bacterial lysis during production and 
purification of phage.The bigger size, is due to the inclusion of several phages in 
same nanoparticles or from the phage particle fragmented.It should be noted that 
homogenization causes the larger sizes of the two curves becomes smaller, which 
gives an idea of disaggregating the various impurity of phage particles.
Lipid nanoformulation
parameters
Designed
starting
conditions
With +25%
Softisan
With +25%
Lecitina
With +25%
Lutrol
With +25%
Tween
With +25%
of Tween
 and +25%
 Lecitina
Homogenization speed (rpm) 9000 9000 9000 9000 9000 9000
Temperature(ºC) 40 40 40 40 40 40
Internal T4 Phage (mg) 10.14 10.14 10.14 10.14 10.06 10.06
aqueous HCL 0,010 M (ml) 1 1 1 1 1 1
phase Tween 80 (mg) 59.4 59.4 59.4 59.4 63.3 63.3
Softisan 100 (mg) 501.7 639.9 504.5 511.9 497.1 503
Oil phase Soybean Lecithin (mg) 49.9 50.6 63.6 50.2 50.6 63.4
Glycerol (ml) 5 5 5 5 5 5
External Lutrol F68 (mg) 403.18 403.18 403.18 500.6 403.18 403.18
aqueous phase Ultrapure H2O (ml) 40 40 40 40 40 40
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Figure 8. Changes in Intensity throughout Particle Hydrodynamic Size.
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